Isofol Medical Q4 2022: Uncertain future - Redeye
Redeye comments on Isofol Medical’s Q4 2022 report after shareholders voted against the board’s proposal to distribute excess cash as a dividend and liquidate the company. We view a reverse takeover as another way forward for the company, though the current management and board do not seem to favour this path. Trying to get arfolitixorin to the market is the third, though in our opinion, the worst option. A new board of directors will be elected on 28 February 2023, who will determine Isofol’s future, we understand.
Länk till analysen i sin helhet: https://www.redeye.se/research/882405/isofol-medical-q4-2022-uncertain-future?utm_source=finwire&utm_medium=RSS
